Prelude Therapeutics Inc (NAS:PRLD)
$ 3.82 0.115 (3.1%) Market Cap: 209.83 Mil Enterprise Value: 18.95 Mil PE Ratio: 0 PB Ratio: 0.99 GF Score: 38/100

Prelude Therapeutics Inc at H C Wainwright Precision Oncology Conference (Virtual) Transcript

Oct 20, 2021 / 05:30PM GMT
Release Date Price: $17.95 (-0.28%)
Robert Burns
H.C. Wainwright & Co. - Analyst

For our next fireside chat, I am joined by Dr. Kris Vaddi, the CEO of Prelude Therapeutics. Dr. Vaddi, thank you for joining us today.

Kris Vaddi
Prelude Therapeutics Inc. - CEO

Thank you. Thank you for the invitation to join.

Questions & Answers

Robert Burns
H.C. Wainwright & Co. - Analyst

Well, I certainly look forward to a lively discussion especially with all the data sets that were recently released at the triple meeting. But before we get into the pipeline and all the data that was released, for those who may be new to the Prelude story, can you provide a brief high-level overview of Prelude's discovery and development approach, as well as the pipeline that you've developed around that approach?

Kris Vaddi
Prelude Therapeutics Inc. - CEO

Yes, absolutely. For those of you who are new to Prelude's story, we are recently public. About a year ago, we went public, but we are a five-year-old company that

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot